Close
Solutions
Online Inquiry
Global Services

NSCAR-γδ T Cell Development Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

γδ T cell therapy is an ideal approach for cancer immunotherapy. Empowered by leading technology and years of experience in cellular therapy solutions, Creative Biolabs is now dedicated to developing NSCAR-γδ T cell services.

CAR-T therapy is successful immunotherapy in hematological tumors but limited in solid tumors. CAR- γδ T cells is an alternative approach to improve CAR-T therapy. CARs commonly consist of an extracellular antigen-binding domain that is most commonly a single-chain variable fragment (scFv) of a mAb linked to intracellular signaling components such as CD3ζ alone or combined with one or more costimulatory domains. Appropriate compositional and structural design of CARs can reduce off-target effects and enhance tumor eradication and persistence.

Design parameters of each module of the CAR.Fig.1 Design parameters of each module of the CAR. (Jayaraman, 2020)

A strategy of the structural design of CARs is to design non-signaling CARs (NSCARs). NSCARs lack the intracellular signaling domains typically present in a CAR. NSCARs are non-activating in αβ T cells and don't enhance αβ T cell cytotoxicity against tumor cells. Unlike αβ T cells, NSCARs are introduced into γδ T cells to enhance target cell killing, because γδ T cells possess alternative mechanisms of cytotoxicity such as NKG2D engagement, Fas-FasL interactions, and do not require stimulation through CD3ζ in order to initiate target cell killing. NSCARs expressed on the surface of γδ T cells specifically recognize tumor antigens and provide direction towards tumor cells. While the cells are in close proximity, the cytotoxic mechanisms endogenous to γδ T cells can engage, ultimately resulting in tumor cell death.

NSCAR-γδ T cells and their cytotoxic mechanisms.Fig.2 NSCAR-γδ T cells and their cytotoxic mechanisms. (Fleischer, 2020)

With our CAR development platform and advanced technologies, Creative Biolabs provides CAR design and construction services specific for a variety of target antigens. If you are interested in our services, please feel free to contact us.

References

  1. Jayaraman, J.; et al. CAR-T design: Elements and their synergistic function. EBioMedicine, 2020, 58: 102931.
  2. Fleischer, L.C.; et al. Non-signaling chimeric antigen receptors enhance antigen-directed killing by γδ T cells in contrast to αβ T Cells. Molecular Therapy-Oncolytics, 2020, 18: 149-160.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.